Zug, Switzerland, 22nd January 2026 – PSI CRO, a global, Swiss-based CRO, closed 2025 as its strongest year to date, marking its 30th anniversary with solid operational and financial performance. The only fully independent and privately owned global CRO, the company achieved 15% revenue growth, a 52% new customer growth, and a 93% repeat business rate while continuing global expansion fueled by its unique delivery model.
In their annual report, PSI highlighted several key sponsor-specific takeaways:
- In an industry characterized by unpredictability, PSI’s key differentiator is on-time project delivery. FPI and LPI were achieved as planned in 95% and 97% of studies – an improvement on 2024 metrics. Sponsors could maintain study momentum, manage budgets effectively, and bring new treatments to patients quicker
- Revenue growth of 15%, supported by a strong backlog and a D&B rating of 1 (the highest performing financial status) indicates sponsors continue to have confidence in PSI’s longevity and commitment to running trials with minimal risk of disruption
- Beyond data demonstrating continued industry leadership in oncology, IBD and GI, radiopharmaceuticals, neuroscience, and infectious disease, growth in other therapeutic areas means sponsors can rely on PSI’s expertise no matter the therapeutic area, reducing risk and improving predictability in complex, pivotal trials
- Operational highlights included the formal launch of the Specialized Study Support Services team (to absorb the operational burden that sites can face, so that enrollment, data quality, and timelines don’t suffer), and a 38% increase in global site activation from last year
- The launch of SYNETICTM, an agentic AI platform bringing years of global site performance data to generate accurate site lists, faster startup, and more predictable enrollment for sponsors
PSI’s strategic promises for 2026 only echo the above. The desire to improve upon predictability in an industry known for its volatility. Increasing and expanding operational presence in top-enrolling regions and continuing to grow global teams are two pledges that are sure to strengthen the metrics for 2026, and help sponsors achieve their goals.
About PSI
PSI CRO is a global full-service contract research organization (CRO), committed to being the best CRO in the world as measured by its employees, customers, investigators, and vendors. PSI’s key operational differentiator is on-time delivery of clinical trials. This metric remained above 90% in 2025.
The company specializes in pivotal phase 2 and phase 3 clinical trials in oncology, hematology, gastroenterology, autoimmune, infectious diseases, neurology, and other indications. PSI provides expertise in complex trials at the forefront of precision medicine, including platform and umbrella designs, trials in targeted immunotherapy, radiopharmaceuticals, and cell and gene therapies.
In 2025, PSI celebrated its 30th year of business as the only fully independent and privately owned mid-sized CRO. PSI employs over 3,200 people across 58 countries as of December 31st, 2025.
Global headquarters are in Switzerland at 113a Baarerstrasse, Zug 6300.
For more information, visit www.psi-cro.com.
For Media Inquiries
Paul Mirek
